文献速递类风湿关节炎

Toll样受体8是类风湿关节炎的治疗靶点

Toll-Like Receptor 8 is a Therapeutic Target in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2026-04-13

本研究探讨Toll样受体8(TLR8)在类风湿关节炎(RA)中的致病作用及其作为治疗靶点的潜力。通过体外和体内模型发现,TLR8在RA患者中异常高表达并与疾病活动度正相关,TLR8抑制可减轻滑膜增生、血管生成和炎症,在CIA小鼠和RA兔模型中显示治疗 efficacy。

要点

  • TLR8在RA患者中异常高表达,与疾病活动度呈强正相关。
  • TLR8抑制可减轻滑膜增生、血管生成和炎症。
  • TLR8拮抗剂在CIA小鼠和RA兔模型中减轻疾病严重度和关节损伤。

核心结论

  • TLR8促进RA发病机制,可能作为RA的新治疗靶点。

研究设计与样本

  • 结合体外和体内模型,分析RA患者与健康对照的基因表达谱,并使用RA患者FLS、HUVEC、PBMC及RA猴细胞建立体外模型。
  • 在CIA小鼠模型和RA兔模型中评估TLR8抑制剂的治疗 efficacy。

主要发现

  • TLR8在RA患者中异常过表达,并与疾病活动度呈强正相关。
  • TLR8上调和激活通过促进滑膜增生、血管生成和炎症驱动RA进展。
  • TLR8抑制可有效缓解上述病理过程。
  • 在CIA小鼠和RA兔模型中,TLR8拮抗剂显著减轻疾病严重度和关节损伤。

临床怎么用

  • TLR8抑制可能成为RA的潜在治疗策略,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to explore the pathogenic role of Toll-like receptor 8 (TLR8) in rheumatoid arthritis (RA) and evaluate its potential as a therapeutic target. Using a combination of in vitro and in vivo models, we explored the functional involvement of TLR8 in RA pathogenesis and assessed the efficacy of TLR8 inhibition. METHODS: Gene expression profiles of patients with RA and healthy controls were analyzed to identify up-regulated genes and pathways. In vitro RA models were established using fibroblast-like synoviocytes (FLSs) from patients with RA, human umbilical vein endothelial cells, and peripheral blood mononuclear cells from patients with RA and RA monkeys and to examine TLR8's role in synoviocyte proliferation, angiogenesis, and inflammation. Additionally, the therapeutic efficacy of a TLR8 inhibitor was evaluated in collagen-induced arthritis (CIA) mouse and RA rabbit models. RESULTS: TLR8 is aberrantly overexpressed in patients with RA and shows strong positive correlations with disease activity. Mechanistically, the up-regulation and activation of TLR8 drives RA progression by promoting synovial hyperplasia, angiogenesis, and inflammation. Notably, TLR8 inhibition effectively alleviates these pathologic processes. In preclinical models, including a CIA mouse model and an RA rabbit model, TLR8 antagonists demonstrated significant therapeutic efficacy, reducing disease severity and ameliorating joint damage. CONCLUSION: TLR8 promotes RA pathogenesis and could serve as a novel therapeutic target for RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Guo Y, Zhu T, Zhang X, et al. Toll-Like Receptor 8 is a Therapeutic Target in Rheumatoid Arthritis. Arthritis Rheumatol. 2026. PMID: 41972505. doi:10.1002/art.70175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。